Apalutamide delays progression of nonmetastatic, castration-resistant prostate cancer

Anne Li                        2/9/18


Treatment with an investigational androgen receptor inhibitor significantly delayed the development of metastasis in patients with prostate cancer that had become resistant to standard androgen-deprivation therapy. The results of a multi-institutional, phase 3 clinical trial of apalutamide — led by investigators from Massachusetts General Hospital (MGH) and University of California, San Francisco (UCSF) — are receiving early release publication in the New England Journal of Medicine to coincide with a presentation today at the American Society for Clinical Oncology Genitourinary Cancers (ASCO-GU) Symposium.


See original article at: https://www.sciencedaily.com/releases/2018/02/180208162013.htm


Post a comment